Almost nothing in longevity research survives contact with a twelve-week trial that people finish. The interesting finding is not which molecule works — it is that adherence predicts outcome better than the molecule does.
3 branches open from this page.
Why the protocol with the best evidence often loses to the one that fits the week.
Continue 02PartWhat the trials measured, what they excluded, and where the effect actually comes from.
Continue 03PartHow to turn a finding into a room, a sequence, and a visible check that survives a bad week.
ContinueThe investigation is the long read: a single question followed all the way down to its sources instead of stopping at a summary.
This page belongs to a journal that publishes its methods and its corrections. If a claim here changes, the change is recorded at the level where it was made.
A protocol that survives a bad week beats a better protocol that does not.
Follow the branch cards down. The dossier is deliberately deeper than a feature: each level narrows the claim until only the evidence remains.